Portfolio Lab

Oruka Therapeutics, Inc.

  • Stock
  • Ticker ORKA
  • ISIN US6876041087
  • Nasdaq

Health care · Pharmaceuticals · USA

$95.81 −1.80%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Oruka Therapeutics, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ORKAGlobal equities (VT)

$10,000 grew to $3,173. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −98.2% in 04/2025, measured from the peak in 12/2016. The old peak has not been reached again yet.

1-year return
+255.0%
5-year return p.a.
+41.0%
10-year return p.a.
−10.8%
Volatility p.a.
104.7%
Largest decline
−98.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Operating income-30-25-28-34-34-36-50-62
EBITDA-30-25-28-34-34-36-50-62
Net income-26-21-25-30-30-32-41-50
Earnings per share2.21-0.40-0.46–––––
Balance sheet
Total assets3963773575094895041,1391,231
Liabilities1412142217182534
Equity3823653444874724871,1151,197
Cash628465914750268192
Cash flow
Operating cash flow-19-21-23-22-23-24-33-44
Capital expenditure0.00.00.0-0.1-0.1-0.10.0-0.1
Free cash flow-19-21-23-22-23-24-33-44

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2024 at +56.4%, weakest 2018 at −75.3%. 3 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
9 Nov 2026–
10 Aug 2026–
13 May 2026–
12 Mar 2026–
12 Nov 2025–
11 Aug 2025−$0.46
14 May 2025−$0.40
6 Mar 2025$2.21
13 Nov 2024−$1.46
1 Aug 2024−$6.96
25 Apr 2024−$0.14
1 Feb 2024−$0.08

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€5.9bn
Market cap in trading currency
$6.50bn
Enterprise value
$5.58bn
P/E
–
P/S
–
P/B
5.43
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
-1.9%

Results (last four quarters)

Revenue
–
Gross profit
–
EBITDA
−$183m
Net income
−$153m
Earnings per share
–
Revenue per share
–
Revenue growth
–
Earnings growth
–

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
-18.1%
Return on assets
-12.4%

Balance sheet and cash flow

Cash
$920m
Cash per share
$13.57
Financial debt
–
Debt/equity %
–
Current ratio
29.62
Book value per share
$17.65
Operating cash flow
−$124m
Free cash flow
−$124m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
67.8m
Volume
1.96m
Avg. volume 3 months
955,276
Relative volume
2.1

Price and technicals

Price
$95.81
1 day
−1.8%
52-week high
$113.08
52-week low
$26.40
Distance to 52-week high
−15.3%
Distance to 52-week low
+262.9%
Distance to 50-day line
+6.3%
Distance to 200-day line
+29.1%
RSI (14)
50
Volatility 1M
66.6%

Performance

1 week
−9.1%
1 month
+18.1%
3 months
−6.5%
6 months
+58.1%
YTD
+216.1%
1 year
+239.0%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ORKA performed since 11/2016?

$10,000 grew to $3,173 by 20 Nov 2026, which is −10.8% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ORKA?

Volatility was 104.7% per year, measured on monthly returns. The largest decline from a peak was −98.2%, with the low in 04/2025.

How does ORKA compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, ORKA returned −10.8% at 104.7%. The correlation of monthly returns was 0.16; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Oruka Therapeutics, Inc. (ORKA): Return and risk